Zacks Research Has Bullish Estimate for Exelixis Q4 Earnings

Exelixis, Inc. (NASDAQ:EXEL) – Equities research analysts at Zacks Research raised their Q4 2027 earnings per share (EPS) estimates for shares of Exelixis in a report released on Thursday, September 3rd. Zacks Research analyst Team now expects that the biotechnology company will post earnings of $1.01 per share for the quarter, up from their previous forecast of $1.00. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Exelixis’ current full-year earnings is $3.19 per share. Zacks Research also issued estimates for Exelixis’ Q2 2028 earnings at $1.00 EPS and FY2028 earnings at $4.21 EPS.

Other research analysts have also recently issued research reports about the company. Morgan Stanley raised their price target on Exelixis from $50.00 to $53.00 and gave the company an “equal weight” rating in a research report on Thursday, July 23rd. Stifel Nicolaus boosted their price objective on shares of Exelixis from $47.00 to $51.00 and gave the stock a “hold” rating in a research report on Thursday, August 6th. Wells Fargo & Company increased their price objective on shares of Exelixis from $40.00 to $49.00 and gave the company an “equal weight” rating in a research note on Monday, July 13th. HC Wainwright restated a “buy” rating and set a $56.00 target price on shares of Exelixis in a report on Thursday, July 2nd. Finally, Wall Street Zen cut shares of Exelixis from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Exelixis presently has a consensus rating of “Hold” and a consensus target price of $50.07.

Exelixis Stock Performance

EXEL opened at $59.13 on Friday. The company has a market cap of $14.65 billion, a price-to-earnings ratio of 18.59, a PEG ratio of 1.74 and a beta of 0.42. Exelixis has a one year low of $33.76 and a one year high of $59.72. The business’s fifty day moving average is $54.98 and its two-hundred day moving average is $49.44.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.06. The firm had revenue of $628.69 million during the quarter, compared to the consensus estimate of $636.40 million. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.Exelixis’s quarterly revenue was up 10.6% on a year-over-year basis. During the same period last year, the business posted $0.75 EPS.

Insiders Place Their Bets

In other Exelixis news, Director Mary Beckerle sold 9,812 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $53.66, for a total transaction of $526,511.92. Following the completion of the transaction, the director owned 16,079 shares of the company’s stock, valued at approximately $862,799.14. This trade represents a 37.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On Exelixis

Hedge funds have recently modified their holdings of the company. Motiv8 Investments LLC acquired a new position in shares of Exelixis in the fourth quarter valued at approximately $26,000. Cassaday & Co Wealth Management LLC purchased a new stake in Exelixis in the 1st quarter worth approximately $27,000. Acumen Wealth Advisors LLC acquired a new position in Exelixis in the 4th quarter valued at $29,000. Western Wealth Management LLC acquired a new position in Exelixis in the 1st quarter valued at $29,000. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in shares of Exelixis by 1,380.4% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 773 shares during the period. 85.27% of the stock is owned by institutional investors and hedge funds.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.